SGN-CD48A

About This Treatment

Myeloma Clinical Trials


A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

This study will test the safety and activity of SGN-CD48A given every 3 weeks to patients with multiple myeloma.

Learn more about this trial

Treatment Information
Developed By

Seattle Genetics

Treatment Classifications

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;